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HIV integrase (IN) cleaves two nucleotides off the 3' end
of viral DNA and integrates viral DNA into target DNA.
Previously, three functional domains in the HIV IN
protein have been identified: (i) the central catalytic
domain, (ii) the C-terminal DNA binding domain, and
(iii) the N-terminal region, which is also necessary for
activity. We have now investigated whether IN proteins
mutated in different domains can complement each other.
Mutant D1161 does not contain an intact active site, but
does bind DNA, whereas the C-terminal deletion mutant
CA73 does not bind DNA, but does have an intact active
site. Neither mutant protein mediates site-specific
cleavage or integration. However, a mixture of both
proteins is active, suggesting that IN functions as an
oligomer, and that two subunits can have different
functions; one subunit binds the (viral) DNA and another
subunit provides the active site. We found three classes
of mutants, corresponding to the three domains
mentioned above. Mutants from different classes, but not
from the same class, can complement each other.
However, complementation is most efficient when the
N- and C-termini are present on the same molecule.
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Introduction
Integration of viral DNA into the human chromosome is an
essential step in HIV replication (Stevenson et al., 1990;
LaFemina et al., 1992). Integration is catalysed by the viral
integrase (IN) protein. After reverse transcription of the viral
genomic RNA, IN removes two nucleotides from the 3' ends
of the linear viral cDNA (donor cut) (Katzman et al., 1989;
Roth et al., 1989; Sherman and Fyfe, 1990; Vora et al.,
1990). Donor cut is a one-step reaction: IN makes a specific
phosphodiester bond accessible for nucleophilic attack
(Engelman et al., 1991; Vink et al., 1991). The natural
nucleophile is probably water, resulting in the release of a
dinucleotide with a 5' phosphate and a 3' hydroxyl group.
However, other nucleophiles, such as glycerol or the
alcoholic amino acid serine (Vink et al., 1991), or the 3'
hydroxyl group of the viral DNA (Engelman et al., 1991)
can also be used.
The newly formed 3' hydroxyl ends of the viral DNA are
coupled to phosphate groups in the target DNA (strand
transfer) (Craigie et al., 1990; Katz et al., 1990; Bushman
and Craigie, 1991). Strand transfer is a one-step reaction:
a phosphodiester bond in the target DNA is broken and a
new one (between viral DNA and target DNA) is made in
one concerted reaction (Engelman et al., 1991). The viral
3' hydroxyl ends are coupled to phosphate groups in opposite
strands of the target DNA, a few base pairs apart.
Subsequently, the gaps are filled in, resulting in an integrated
provirus flanked by a duplication of a short stretch of the
target sequence (reviewed in Varmus and Brown, 1989).
Mutational analyses of HIV-1 (Drelich et al., 1992;
Engelman and Craigie, 1992; Kulkosky et al., 1992; Vink
et al., 1993) and HIV-2 IN (van Gent et al., 1992) have
identified three distinct regions in the protein.
(i) The N-terminus is required for donor cut and strand
transfer (Bushman et al., 1993; Vincent et al., 1993; Vink
et al., 1993). This region contains the zinc-finger-like motif
His-Xaa3-His-Xaa20 30-Cys-Xaa2-Cys, which has been
shown to bind Zn2+ (Burke et al., 1992; Bushman et al.,
1993). Mutation of each one of the His or Cys residues
results in reduction of IN activity, especially donor cut
(Engelman and Craigie, 1992; LaFemina et al., 1992; van
Gent et al., 1992). The function of this region is not clear yet.
(ii) The central region, approximately between amino acids
60 and 160, is the most conserved part of retroviral integrases
(Fayet et al., 1990; Khan et al., 1991). Mutational analysis
identified three potential active-site residues in this region.
Asp64, Aspi 16 and Glu 152; mutation of each one of these
residues leads to inactivation of IN (Drelich et al., 1992;
Engelman and Craigie, 1992; Kulkosky et al., 1992; van
Gent et al., 1992). These amino acids are conserved among
all retroviral integrases and also in transposases of certain
bacterial insertion sequences (Fayet et al., 1990; Khan et
al., 1991). They will be referred to as active-site residues.
In general both donor cut and strand transfer activity are
equally affected by mutations in IN, indicating that both
activities are probably carried out by one active site.
(iii) The C-terminus is the least conserved part of retroviral
integrases. It contains a DNA binding domain (Khan et al.,
1991; Mumm and Grandgenett, 1991; Woemer etal., 1992),
located between amino acids 200 and 270 of the 288 amino
acid HIV-1 IN protein (Vink et al., 1993). HIV IN has only
slightly more affinity for specific than for non-specific DNA
(LaFemina et al., 1991; van Gent et al., 1991).
Here we report that mixing of different classes of inactive
IN mutants restores activity. One subunit can provide the
C-terminal DNA binding domain (and preferably also the
N-terminus), and the other one the active site. This suggests
that IN is active as a dimer (or oligomer), in which the
different subunits can have different functions.
Results
Complementation between active-site mutants and
C-terminal deletion mutants
We expressed and purified the HIV-2 IN active-site mutants
D64V, D1 16I and E152L, and a C-terminal deletion mutant
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Fig. 1. Activities of mutant HIV-2 IN proteins. (A) Cleavage, (B) integration and (C) disintegration reactions using immobilized proteins. The
nomenclature is as follows: the first letter signifies the amino acid in wild-type HIV-2 IN, then the position of the residue is given and the amino
acid into which this residue is changed. C-terminal deletion mutants are named CA followed by the number of amino acids that have been deleted
from the C-terminus, and N-terminal deletion mutants are indicated by NA followed by the number of amino acids that have been deleted from the
N-terminus. G, glycerol product; C, cyclic dinucleotide; D, linear dinucleotide; IP, integration products; WT, wild-type HIV-2 IN; DNase, DNase I
degradation ladder of the oligonucleotide used. The positions of the 28-mer cleavage substrate, the 26-mer integration substrate, the 13-mer
disintegration substrate, and the 29-mer disintegration product are indicated on the left. A schematic representation of the substrates is drawn below
the autoradiographs; the position of the radiolabel is depicted by an open circle.
of HIV-2 IN containing amino acids 1-220 (CA73). These
mutants do not mediate site-specific cleavage or integration
of viral DNA (Figure IA and B). In contrast to the active-
site mutants, the deletion mutant contains an intact active
site, which is inferred from the ability of the deletion mutant
to perform the reversal of the integration reaction, called
disintegration (Chow et al., 1992; Figure IC). The level of
disintegration by the deletion mutant, however, is reduced
compared with wild-type ( 6% of the wild-type level). The
C-terminus of the HIV-1 IN has been found to contain a
DNA binding domain (Woerner et al., 1992; Vink et al.,
1993). In agreement with this finding for HIV-1, the HIV-2
IN mutant CA73 does not bind DNA, whereas the active-
site mutants do (data not shown).
Several recombination proteins act as dimers or oligomers
in site-specific recombination reactions. Kinetic analysis of
Rous sarcoma virus IN indicates that IN acts as an oligomer
in cleavage and integration (Jones et al., 1992). We studied
whether different subunits of IN might play different roles
in the reaction. To investigate whether an active-site mutant
could rescue a DNA binding mutant, we mixed the active-
site mutant D1 16I and the C-terminal deletion mutant CA73,
and assayed the mixture for site-specific cleavage and
integration. Both mutant proteins alone are inactive; the
mixture, however, mediates both reactions (Figure 2A and
B). We found that a mixture of approximately equimolar
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Fig. 2. Complementation between the HIV-2 IN mutants CA73 and
DI 161. Cleavage (A) and integration (B) reactions were carried out
with CA73 (lane 1), D 161 (lane 7) and mixtures of these mutants
(lanes 2-6). The proteins were mixed in molar ratios of 9:1, 3:1,
1:1, 1:3 and 1:9 respectively in lanes 2-6. The abbreviations were as
in Figure 1. Figures 1, 2 and 3 are the same exposure of different
parts of the same gel.
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amounts of the two mutants yielded the highest activity
(Figure 2A and B). Since an active-site mutant acts together
with the deletion mutant, we conclude that HIV IN can act
as a dimer or oligomer in both cleavage and integration. One
subunit probably binds the (viral) DNA and another subunit
provides the active site for hydrolysis of a specific phospho-
diester bond in the viral DNA, or integration of viral DNA
into target DNA (see Discussion).
Previously, two other active-site residues were identified:
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Fig. 3. Complementation between HIV-2 IN active-site mutants and
the C-terminal deletion mutant CA73. Cleavage (A) and integration (B)
reactions with mixtures of mutant HIV-2 IN proteins. The
abbreviations were as in Figure 1. Figures 1, 2 and 3 are the same
exposure of different parts of the same gel.
Asp64 and Glu152 (Drelich et al., 1992; Engelman and
Craigie, 1992; Kulkosky et al., 1992; van Gent et al., 1992).
The active-site mutants D64V and E152L were also tested
for their ability to complement the C-terminal deletion mutant
CA73 and each other. As shown in Figure 3, they indeed
complement mutant CA73 (although mutant E152L
somewhat less than the other two active-site mutants). They
do not complement mutant DI 16I nor each other, showing
that they are members of the same complementation group.
We investigated which part of the C-terminus is required
for complementation using a series of fusion proteins of
maltose binding protein and (mutant) HIV-1 IN (Vink et al.,
1993). As shown in Figure 4, the wild-type fusion protein
mediates site-specific cleavage and integration, whereas the
active-site mutant MD1 16I and the C-terminal deletion
mutants do not. However, mixtures of the active-site mutant
and the C-terminal deletion mutants, were active. Comple-
mentation was very efficient with the short deletions MCA51
and MCA66, weak with the larger deletion mutants MCA81
and MCA94, and only detectable after prolonged exposure
with the largest deletion mutants MCA105 and MCA1 17
(Figure 4A and B and Table I). The gradual decrease in the
level of complementation parallels the gradual loss of
disintegration activity of these mutants (Figure 4C and
Table I).
All experiments described above have been performed
with IN preparations that were immobilized (after mixing).
These preparations contain a lower non-specific nuclease
background, and remain active for a longer period of time,
resulting in a much higher level of cleavage and integration
(van Gent et al., 1992). We performed some of the reactions
also with soluble proteins and found that the results were
similar to what was found for immobilized proteins (Table 1).
To investigate the specificity of the interactions between
HIV IN monomers, we asked whether HIV-1 and HIV-2
IN mutants could complement each other. We found that
the HIV-2 deletion mutant CA73 could complement the
HIV-1IN active-site mutant MD1 161 in both site-specific
cleavage and integration (data not shown). The level of
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Fig. 4. Complementation reactions with C-terminal deletion mutants and an active-site mutant of fusion proteins of maltose binding protein and
HIV-1 IN. (A) Cleavage, (B) integration and (C) disintegration reactions. The abbreviations and nomenclature are as in Figure 1, the 'M' is added
to signify that a mutant is a fusion protein of maltose binding protein and HIV-1 IN. WT, fusion protein of maltose binding protein and wild-type
HIV-1 IN. The band at the 16-mer position is probably the result of reintegration (integration following disintegration; Vink et al., 1993).
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Table I. Complementation between HIV-1 IN mutants
Mutant +MD116I +MNA50 +MCA51
cl int dis cl int cl int cl int
MNA5 ++ ++ +++ + + +++ nd nd nd nd
MNA23 - - +++ +++ +++ nd nd ++ ++
MNA50 - - +++ +++a +++ nd nd ++a ++
MCA51 - - +++ +++a +++ ++a ++ nd nd
MCA66 - - +++ ++ ++ + + nd nd
MCA81 - - + + + + nd nd nd nd
MCA94 - - + + + + nd nd nd nd
MCA105 - - - _ nd nd nd nd
MCAl117 - - - _ _b nd nd nd nd
MNA50/CA51 - - + + + + + + + nd nd nd nd
MNA50/D1 161 - - nd nd + +
MCA5l/D116I - - - nd nd + + + nd nd
aThese reactions were also performed in solution and yielded similar results; MNA50 + MD1 161, +++; MCA51 + MD1 161, + +; MNA50 +
MCA5 1, +.
bThese reactions yielded a very low level of integration products, only detectable after prolonged autoradiography.
The levels of activity of the various mutants were determined by scanning of autoradiographs and comparison with the fusion protein of maltose
binding protein and wild-type HIV-1 IN. The nomenclature of mutants is as in Figure 4, cl, site-specific cleavage; int, integration; dis, disintegration.
The activity is scored as follows: + + +, >40% of wild-type activity; + +, 10-40% of wild-type activity; +, 1-10% of wild type activity;
- <1% of wild-type activity; nd, not determined.
complementation, however, was lower ( - 5% of wild-type
HIV-1 or HIV-2 IN) than between HIV- 1 IN mutants
MCA66 and MDl 16I (37% of wild-type level) or between
HIV-2 IN mutants CA73 and DI 161 (30% of wild-type
level), suggesting that the interaction between IN subunits
is rather specific and that dimerization signals are not
completely conserved between HIV-1 and HIV-2.
N-terminal deletion mutants from a separate
complementation group
Previously the N-terminus has been identified as a region
in the protein that is required for site-specific cleavage and
integration, but not for disintegration (Bushman et al., 1993;
Vink et al., 1993). An N-terminal deletion mutant in which
the first five amino acids have been deleted (MNA5) mediates
site-specific cleavage and integration at a reduced level
compared with the wild-type protein (Figure 5 and Table
I). Larger deletions up to 50 amino acids are inactive in these
two reactions, but can still mediate disintegration (Table I).
Deletion of 72 amino acids from the N-terminus results in
a protein that does not mediate disintegration, presumably
because part of the active-site (including residue Asp64) has
been deleted.
N-terminal deletion mutants were tested for their ability
to complement the active-site mutant MD 1 16I. Mixtures of
both types of mutants mediate site-specific cleavage and
integration (Figure 5 and Table I). Mutant MNA72 does not
complement mutant MD1 16I, which is in line with the
hypothesis that this deletion mutant lacks part of the active
site.
In order to find out whether the N-terminal and C-terminal
deletion mutants belong to the same complementation group,
we also mixed both types of deletion mutant. As shown in
Figure 6 and Table I they complement each other, showing
that they belong to different complementation groups, and
that the N-terminus can be provided in trans to the C-terminal
DNA binding region. Complementation between N-terminal
and C-terminal deletion mutants is, however, less efficient
than between either of the deletion mutants and the active-
site mutant. In summary, we identified three complementa-
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Fig. 5. Complementation between N-terninal deletion mutants and an
active-site mutant. (A) Cleavage and (B) integration reactions.
Nomenclature is as in Figure 4, abbreviations as in Figure 1.
tion groups that correspond to the three domains that were
previously characterized.
The three domains can be provided either in cis or
in trans
As shown above, we identified three classes of mutants that
can complement each other. In other words, the three
domains can be supplied from different molecules. We
investigated whether a protein mutated in two domains could
complement a protein mutated in the third domain (schem-
atically depicted in Figure 7A). We constructed a set of
mutants containing two mutations of different complementa-
tion groups and mixed them with a mutant from the third
group. When the N- and C-termini are present on one
molecule and the active site on another one (Figure 7A,
combination 4), complementation is rather efficient (Figure
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Fig. 6. Complementation between N- and C-terminal deletion mutants.
(A) Cleavage and (B) integration reactions. Nomenclature is as in
Figure 4, abbreviations as in Figure 1.
7B and C and Table I), only - 2-fold lower than between
an active-site mutant and a mutant containing either the
N-terminal or the C-terminal deletion alone (Figure 7A,
combinations 1 and 2). Complementation between N- and
C-terminal deletion mutants is less efficient than between
either of these and an active-site mutant. If the N- and
C-termini are present on separate molecules, complementa-
tion is-more efficient when the active site is present on the
same molecule as the C-terminus (Figure 7A, combination
6 and 7B and C) than when it is located on the other molecule
(Figure 7A, combination 5 and 7B and C). In conclusion,
these experiments show that the N-terminus and the
C-terminal DNA binding domain should preferentially be
present on the same molecule, and the active site on another
one. However, other combinations can also complement each
other, suggesting that there is a high degree of flexibility
in the interactions between these three domains.
Deletion of the N-terminal 72 amino acids deletes part of
the active site. Therefore, one would expect that it belongs
to the same class of mutants as the double mutant in which
both the N-terminal 50 amino acids have been deleted and
the active site has been disrupted by a point mutation (Figure
7A, combination 6). However, this mutant does not
complement the C-terminal deletion mutant (Figure 7B and
C, lane 16). This indicates that the region between amino
acids 50 and 72 is either important for dimerization or that
this mutant does not fold correctly. Mixing all three double
mutants together did not result in preparations that contain
detectable cleavage and integration activity (data not shown).
This indicates that functional complementation can only
occur between two and not between three IN monomers.
Discussion
Three IN complementation groups
HIV IN contains three regions that are important for activity:
(i) the central catalytic domain, contained within amino acids
50-194, (ii) the DNA binding domain, between amino acids
200 and 270, and (iii) the N-terminal region, spanning
residues 1-50. IN mutants deleted in the N-terminal region
or the C-terminal DNA binding region contain an intact
active site, but are no longer able to carry out site-specific
cleavage of the viral DNA termini or DNA strand transfer.
However, mixing of these deletion mutants with active-site
mutants restores both site-specific cleavage and strand
transfer activity, showing that these domains can be supplied
on different IN molecules. This shows that IN molecules
can interact functionally with each other, and suggests that
IN functions as oligomer. However, we cannot formally
exclude that wild-type HIV IN might be able to act as a
monomer. In that case one would have to assume that the
IN domains of the same monomer of wild-type IN interact,
and that only in our complementation experiments do the
domains of different monomers functionally interact. This
would require a very high degree of flexibility of the
relatively small IN protein, which is why we favour the
interpretation that functional interaction between mutant
monomers suggests that wild-type IN also acts as oligomer.
Functional complementation was not observed between
different active-site IN mutants. These mutants therefore
belong to the same complementation group, which is
consistent with the hypothesis that Asp64, Aspi16 and
Glu152 are key residues within the single active site of IN.
The other complementation groups are formed by N-terminal
deletion mutants and IN mutants that have deletions of the
C-terminal DNA binding region. Similar results were
independently obtained by Engelman et al. (see accompany-
ing paper): they identified similar complementation groups,
and reach the conclusion that IN contains three more or less
independently functioning domains. Minor differences in
levels of complementation can be attributed mainly to
differences in definition of activity levels and in reaction
conditions.
Oligomerization of IN
Mutant IN proteins that contain amino acids 50-220
efficiently complement active-site mutants. Efficient
complementation between IN mutants is no longer observed
when a single mutant has a deletion of > 50 residues from
the N-terminus or more than - 70 residues from the
C-terminus. This might indicate that the region between
amino acids 50 and 220 of HIV IN is important for
oligomerization. The signals that govern oligomerization
remain to be determined.
Based on the symmetry of the integration reaction, in
which the two viral DNA ends are inserted into both strands
of the target DNA, it is likely that an even number of IN
monomers is involved in the process. Models have been
proposed in which either IN dimers (Vink et al., 1991;
Vincent et al., 1993) or IN tetramers (Engelman et al., 1991)
carry out the concerted integration of one viral DNA
molecule. A tetrameric IN complex is consistent with the
results presented here: cleavage and integration of one viral
DNA end is accomplished by (at least) two IN molecules,
suggesting that integration of two DNA termini would
require (at least) four IN molecules.
Intra-protein complementation
The results presented here suggest that one IN subunit binds
the viral DNA terminus and that another subunit provides
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Fig. 7. Complementation reactions using double mutants. (A) Schematic representation of the complementation between the various single and double
mutants. X, mutation of the active-site residue Aspll6 to Ile, shorter bars indicate deletions. The names of the various mutants are indicated below
the mutants. The level of site-specific cleavage (cl) and integration (int) is shown behind the combinations; the levels of activity are determined as
described in Table I. (B) Cleavage and (C) integration reactions. The abbreviations are as in Figure 1, nomenclature as in Figure 4. A slash signifies
that two mutations are present in the same IN protein.
the active site for site-specific cleavage. The only other
recombinase for which complementation between different
mutant proteins has been described is Flp recombinase from
Saccharomyces cerevisiae (Chen et al., 1992). Flp contains
a catalytic domain with four amino acids that are conserved
among the It family recombinases. The key catalytic residue
within one monomer, Tyr343, forms a catalytic site in
conjunction with the other three invariable residues of
another Flp monomer. This tyrosine residue leads the
nucleophilic attack on the target phosphodiester bond in the
DNA cleavage step of Flp recombination. Tyr343 attacks
DNA in trans; a DNA site is not cleaved by the Flp monomer
which is bound to it, but rather by a second Flp monomer.
IN is probably also active in trans: the active site can be
provided by an IN monomer that is not able to bind DNA.
It is not clear whether the active site is provided by an IN
molecule that is bound to another DNA site or by an IN
molecule that forms a dimer on one viral DNA end. In
contrast to Flp, IN active-site mutants cannot complement
other active-site mutants.
Protein - protein interactions in the synaptic complex
It has been observed that if one terminus of Moloney murine
leukemia virus DNA contains a mutation that prevents
cleavage, the other (wild-type) viral DNA end is also not
cleaved in vivo (Murphy and Goff, 1992). These results
suggest that in vivo a specific oligomeric complex is formed
in which both wild-type viral DNA ends should be present
before cleavage can occur. Such a mechanism of cleavage
might ensure that both viral DNA termini are brought
together before cleavage occurs. A similar mechanism of
strand transfer could ensure concerted integration of both
viral DNA ends into target DNA. Transposition of several
transposons involves formation of a synaptic complex, in
which the two transposon ends and target DNA are held
together by an oligomeric complex of transposase molecules.
The stable synaptic complexes formed by the bacteriophages
mu and lambda contain four molecules of MuA transposase
and Int protein, respectively (Kim et al., 1990; Lavoie et al.,
1991). Binding of one MuA molecule does not protect the
exact transposon ends, but protects a position more internal
in the transposon. Upon formation of the synaptic complex
the protection extends over the transposon ends (Lavoie
et al., 1991). Here we describe how HIV IN consists of
domains that can to some extent act autonomously, in the
sense that three functional domains can be contributed by
two different IN monomers; these results support the notion
of extensive contacts between IN monomers in an oligomeric
complex.
Materials and methods
DNA techniques
Standard DNA procedures were carried out as described (Sambrook et al.,
1989). Point mutants of HIV-1 and HIV-2 IN were generated by site-directed
mutagenesis as described (van Gent et al., 1992). The generation of HIV-1
IN deletion mutants has been described previously (Vink et al., 1993). In
the HIV-2 IN deletion mutant CA73 two stop-codons were introduced 3'
of tiplet codon for amino acid Leu220, and subsequently the region encoding
amino acids 221-280 was deleted. The double mutant MNA50/CA51 was
generated by exchanging restriction fragments between plasmids encoding
proteins MNA50 and MCA51. For the expression of proteins MNA50/D1 16I
and MCA5 1/DI 161 constructs were generated by site-directed mutagenesis
of plasmids encoding MNA50 and MCA51, respectively.
Protein purification
HIV-2 IN was purified and immobilized on Thiopropyl Sepharose as
described (van Gent et al., 1992). For the complementation assays the
purified mutant proteins were mixed, incubated for 30 min at 0°C, and
immobilized on Thiopropyl Sepharose. The total protein concentration was
10 pmol/Al of a 50% slurry of beads. The fusion proteins of HIV-1 IN
and maltose binding protein were purified as described (Vink et al., 1993).
For the complementation assays the purified proteins were dialysed to 20 mM
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Tris-HCl pH 7.5, 1 M NaCl, 1 mM EDTA for 2 h at 4°C, mixed and
incubated for 30 min at OC, and immobilized on Thiopropyl Sepharose
at a total protein concentration of 10 pmol/Al of a 50% slurry of beads.
Unless stated otherwise, proteins were mixed in a 1:1 ratio in the
complementation reactions.
Cleavage, integration and disintegration assays
Oligonucleotide cleavage reactions were done with an HIV- 1 U5 substrate
labelled at the 3' end as described (Vink et al., 1991). Reaction mixtures
contained 20 mM MOPS pH 7.2, 25 mM NaCl, 1 mM (HIV-2) or 3 mM
(HIV-1) MnCl2, 10 mM DTT, 10% (v/v) glycerol, 0.04 /AM oligo-
nucleotide substrate and 1 $M immobilized IN, and were incubated for 1 h
at 300C.
Integration reactions were carried out as described (van Gent et al., 1992).
Reaction mixtures were incubated for 3 h at 300C. Disintegration reactions
were carried out using the Y-shaped substrate depicted in Figure 1 as
described (van Gent et al., 1992). Activities were quantified by densitometry,
using an Ultrascan XL Enhanced Laser Densitometer (LKB).
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